NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data
Corcept Therapeutics (CORT) is back in focus after presenting new CATALYST and MOMENTUM trial data at the American Diabetes Association meetings, highlighting how Korlym might affect difficult-to-control diabetes and resistant hypertension.
See our latest analysis for Corcept Therapeutics.
Corcept’s recent news has added to an already strong run, with a 30 day share price return of 48.22% and a 90 day share price return of 129.67%. The 5 year total shareholder return of 253.35% points to...